Gamma interferon prevents diabetes in the BB rat

Area of Science:

• Immunology
• Endocrinology
• Diabetes Research

Background:

• The BB rat model spontaneously develops autoimmune diabetes, mimicking human insulin-dependent diabetes mellitus (IDDM).
• Gamma interferon (IFN-gamma) is implicated as a pathogenic factor in this autoimmune process.

Purpose of the Study:

• To investigate the potential of exogenous gamma interferon (IFN-gamma) administration to prevent diabetes in BB rats.
• To determine the dose-dependency, optimal treatment duration, and age-dependency of this preventative effect.

Main Methods:

• Diabetes-prone BB rats received intraperitoneal injections of murine recombinant IFN-gamma (rIFN-gamma) at varying doses and durations.
• Treatment initiation age was varied (35-65 days), and effects on diabetes incidence and islet inflammation were assessed.

Main Results:

• rIFN-gamma administration prevented diabetes development in a dose-dependent manner, reducing incidence from 90% to 9.1% in optimal conditions.
• The diabetes-sparing effect was long-lasting (up to 7 months) and effective even when treatment began at 55 days of age (when insulitis is present).
• rIFN-gamma significantly reduced islet inflammation (P < 0.01) without altering peripheral leukocyte counts.

Conclusions:

• Exogenous rIFN-gamma administration potently and paradoxically prevents autoimmune diabetes in BB rats.
• The mechanism involves the inhibition of islet inflammation, demonstrating a therapeutic potential for IFN-gamma in early diabetes intervention.